DoD Prostate Cancer, Exploration - Hypothesis Development Award | HT942524PCRPEHDA

Opportunity Information: Apply for HT942524PCRPEHDA

The FY24 DoD Prostate Cancer Research Program (PCRP) Exploration - Hypothesis Development Award is a small, early-stage grant mechanism meant to let researchers test bold, unproven ideas in prostate cancer that align with one or more of the program's FY24 Overarching Challenges. The emphasis is on high-risk, high-reward concepts that are genuinely exploratory, including brand-new theories, paradigms, methods, or directions sparked by unexpected or "serendipitous" observations. The goal is not to deliver a mature, heavily validated research package, but to generate the kind of initial evidence or scientific premise that can justify a new hypothesis or provide an early proof-of-principle that supports a larger follow-on effort.

A defining feature of this award is that preliminary data are strongly discouraged because they can signal the work is already underway or too developed for an exploration mechanism. Instead, applications are expected to rely on clear logical reasoning and a strong scientific rationale that explains why the idea is worth testing and how the proposed approach could unlock a meaningful advance. The review process is also designed to reduce bias: reviewers will be blinded to the identities of the principal investigator, collaborators, and institutions, which puts extra weight on how clearly the idea, rationale, and experimental plan are presented rather than on the team's reputation or organizational brand.

For FY24, a key change is that clinical research is allowed, as long as it is not a clinical trial. In this announcement, "clinical research" is defined broadly as observational work involving human data, human specimens, and/or interaction with human subjects where the investigator is not prospectively assigning people to an intervention and is not evaluating intervention safety, effectiveness, or efficacy outcomes. Examples include studying mechanisms of human disease, diagnostic or detection research such as biomarker or imaging studies, health disparities research, technology development, epidemiologic or behavioral studies that do not test an intervention, and outcomes or health services research that still does not qualify as a clinical trial. What is explicitly not allowed are clinical trials, defined under 45 CFR 46.102 as studies where human subjects are prospectively assigned to one or more interventions (including placebo or controls) to evaluate effects on biomedical or behavioral health-related outcomes. In other words, observational and translational human-focused research can fit, but intervention testing cannot.

Programmatically, the opportunity also points applicants toward broader federal priorities around advanced and recurrent disease. It highlights recommendations from the congressionally mandated Metastatic Cancer Task Force and encourages research ideas that help accelerate clinical and translational progress for patients with advanced-stage or recurrent cancer, as long as the projects remain within this award's boundaries. The announcement also specifically encourages innovative work in nuclear medicine and related techniques, particularly where it could improve early diagnosis, enable more effective targeted treatment, and improve outcomes for active-duty Service Members and their families. That emphasis signals interest in noninvasive precision imaging, radiotracers, and targeted therapeutic approaches that can improve detection and treatment selection, while still fitting the exploratory nature of the mechanism.

The Department of Defense also places value on collaborations that can speed translation and broaden access to key populations and infrastructure. Applications from investigators within the military services are encouraged, and multidisciplinary partnerships among academia, industry, the military, the Department of Veterans Affairs, and other federal agencies are viewed positively. If a project depends on special resources such as unique patient populations, biobanks, registries, or restricted databases, the application needs to clearly explain how access is already secured at submission and how access will be maintained throughout the project period. The announcement further reinforces expectations for rigor and reproducibility, pointing to widely used best practices around randomization, blinding, sample-size estimation, and transparent data handling and reporting, adapted as appropriate for the type of preclinical or clinical research proposed.

From a funding and administrative standpoint, awards are issued as grants (under 31 USC 6304). The budget is intentionally modest: anticipated direct costs for the entire period of performance should not exceed $150,000. The Army contracting and grants office structure is reflected in the listing: the issuing agency is the Department of the Army (USAMRAA), the opportunity is discretionary, and it falls under CFDA 12.420 for research and development. Eligibility is listed as unrestricted, meaning there are no special categorical limits stated in the synopsis for who may apply, though applicants still must meet standard federal and program requirements.

The program expects to commit about $3.60 million total to make roughly 15 awards, with actual funding dependent on federal fund availability and on peer and programmatic review outcomes. The original closing date listed is July 12, 2024, and awards supported with FY24 funds are expected to be made no later than September 30, 2025. Like many DoD programs, the funds are tied to a fiscal-year lifecycle; the notice indicates FY24 funds used for awards are expected to expire for use on September 30, 2030, which affects how long obligated funds remain available under federal rules.

Finally, for projects involving animals, there is a layered oversight process beyond the local Institutional Animal Care and Use Committee (IACUC). Any new or ongoing animal research funded under this mechanism must also be reviewed and approved by USAMRDC oversight offices, including OHARO and ACURO, in addition to the local IACUC of record. IACUC approval is not required at the time of submission, but the announcement advises planning ahead because DoD-level regulatory review can take roughly 3 to 4 months. This timeline matters for feasibility, especially under a small, time-limited exploratory award where delays can quickly consume the period of performance.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Exploration - Hypothesis Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-05-01.
• Applicants must submit their applications by 2024-07-12. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 15 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524PCRPEHDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: